Fulgent Pharma : Moffitt and Fulgent Pharma partner on personalised cancer therapies

Pharmaceutical Technology · Lightspring / Shutterstock.com. Moffitt Cancer Center and Fulgent Pharma have announced a strategic partnership to enhance the development of personalised therapies for cancer. The companies will join forces to progress therapeutics through pre-clinical co-development and clinical development. The collaboration unites the clinical expertise of Moffitt with Fulgent's nanotherapeutics and genomics platforms to expedite the creation of targeted cancer treatments. The agreement grants Fulgent priority access to Moffitt's clinical capabilities and resources, which will accelerate the progression of Fulgent's clinical pipeline. This includes prioritised activation of clinical trials, improved patient screening and efficient data sharing to deliver investigational therapies to patients swiftly. Fulgent Pharma, with expertise in nanoencapsulation technology, developed a soluble form of the chemotherapy drug paclitaxel, named FID-007. Early Phase I clinical studies have shown significant tumour reduction in breast, head and neck, lung, bile duct, and pancreatic cancers using soluble intravenous FID-007 injection. The partnership will also focus on co-developing new tailored cancer treatments. Moffitt will utilise its extensive scientific and immunology knowledge, tissue sample access and nonclinical research resources. Fulgent will provide its nano-particle-based drug development platform and comprehensive genetic and genomic testing capabilities. Moffitt president and CEO Patrick Hwu stated: "This partnership aligns with Moffitt's mission to contribute to the prevention and cure of cancer. We are looking forward to working with Fulgent to accelerate the translation of scientific discoveries into lifesaving treatments for our patients." In November 2022, Fulgent Pharma was acquired by Fulgent Genetics for $100m . "Moffitt and Fulgent Pharma partner on personalised cancer therapies" was originally created and published by Pharmaceutical Technology , a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.